- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
By combining an iron oxide nanoparticle, a tumor-targeting peptide, and a therapeutic nucleic acid into one construct, a team of investigators from the Massachusetts General Hospital and Harvard Medical School have created an agent that holds potential as targeted therapy for breast cancer. In addition, this new agent can be easily tracked in the body using standard magnetic resonance imaging (MRI).
Zdravka Medarova led this study. She and her colleagues published their results in the journal Cancer Research.
Dr. Medarova and her collaborators created their nanoparticle to bind to a tumor-specific molecules known as uMUC-1, which is found on the surface of over 90 percent of human breast tumors, and deliver a synthetic small interfering RNA (siRNA) molecule designed to shut down a specific gene - BIRC5 - that blocks cell death in most tumors and is associated with the development of drug resistance. The investigators also added a fluorescent dye to their nanoparticle to afford them the ability to track the nanoparticle using near-infrared spectroscopy. Because the nanoparticle itself is composed of superparamagnetic iron oxide, it is readily visible in MRI scans.
When added to breast cancer cells growing in culture, this nanoparticle construct had a profound impact on the expression of the BIRC5 gene, knocking down its expression. Both fluorescence imaging and MRI showed that the nanoparticle was taken up rapidly by the cells. Subsequent experiments showed that this construct had the same positive effect on both human pancreatic cancer cells and colon cancer cells.
Based on these initial results, the investigators injected the nanoparticles intravenously into mice bearing human breast tumors. The drug was administered on two separate occasions, a week apart. Both MRI and fluorescence imaging scans revealed that the nanoparticle accumulated preferentially in the tumors and that tumor levels remained high over the course of the two week experiment. Very little drug accumulated in muscle tissue surrounding the tumors.
When the tumors themselves were examined, the investigators found that the siRNA payload produced a five-fold increase in cell death compared to when animals were instead treated with a similar construct bearing a nonsense siRNA molecule even though the two nanoparticles accumulated to the same level in the tumors of treated animals. This result shows that the therapeutic effect of the construct is independent of its tumor targeting properties and is instead a result of its therapeutic siRNA payload.
This work, which was supported in part by the National Cancer Institute, is detailed in a paper titled, "Image-Guided Breast Tumor Therapy Using a Small Interfering RNA Nanodrug." An abstract of this paper is available at the journal's website.
View abstract at dx.doi.org/doi:10.1158/0008-5472.CAN-10-2070
About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
Copyright © NCI Alliance for Nanotechnology in CancerIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
X-rays and electrons join forces to map catalytic reactions in real-time: New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions June 29th, 2015
Healthcare Nanotechnology (Nanomedicine) Market Size To 2020 June 5th, 2015
Chivalrous Knight Does Pro Bono June 27th, 2015
Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015
Researchers first to show that Saharan silver ants can control electromagnetic waves over an extremely broad range of the electromagnetic spectrum—findings may lead to biologically inspired coatings for passive radiative cooling of objects June 19th, 2015
Cellulose from wood can be printed in 3-D June 17th, 2015